Rigel Pharmaceuticals, Inc.
RIGL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $57 | $33 | $24 | $19 |
| Short-Term Investments | $21 | $24 | $34 | $106 |
| Receivables | $42 | $31 | $40 | $15 |
| Inventory | $6 | $6 | $9 | $7 |
| Other Curr. Assets | $10 | $6 | $8 | $7 |
| Total Curr. Assets | $135 | $99 | $116 | $154 |
| Property Plant & Equip (Net) | $0 | $1 | $3 | $12 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $27 | $14 | $15 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $1 | $3 | $1 | $1 |
| Total NC Assets | $29 | $18 | $18 | $13 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $164 | $117 | $134 | $167 |
| Liabilities | – | – | – | – |
| Payables | $3 | $7 | $23 | $4 |
| Short-Term Debt | $8 | $8 | $1 | $10 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $28 | $17 | $14 | $11 |
| Other Curr. Liab. | $25 | $21 | $28 | $39 |
| Total Curr. Liab. | $63 | $53 | $65 | $64 |
| LT Debt | $52 | $53 | $40 | $21 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $45 | $40 | $42 | $53 |
| Total NC Liab. | $97 | $93 | $83 | $73 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $1 | $2 | $11 |
| Total Liabilities | $161 | $146 | $148 | $137 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$1,390 | -$1,408 | -$1,382 | -$1,324 |
| AOCI | $0 | $0 | -$0 | -$0 |
| Other Equity | $1,393 | $1,379 | $1,369 | $1,354 |
| Total Equity | $3 | -$29 | -$14 | $30 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $164 | $117 | $134 | $167 |
| Net Debt | $3 | $28 | $17 | $12 |